Bao Yiting, Huang Wu, Yao Liangqing, Yuan Lei
Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Gland Surg. 2022 May;11(5):932-937. doi: 10.21037/gs-21-895.
Endometriosis is a disturbing condition affecting about 10% of all reproductive aged women. The most severe form of endometriosis is deeply infiltrative endometriosis (DIE). Bowel is commonly affected in DIE. Treatment options of bowel endometriosis include surgery and medication, depending on many factors such as age, the severity of symptoms and desire for pregnancy. At present, the individualized comprehensive management of bowel endometriosis is still under exploration. Here we report an uncommon case of bowel endometriosis treated by radical surgery and postoperative high-dose progestin to enrich the clinical experience.
A 37-year-old woman was admitted to our hospital for suspected ovarian malignancy in the presence of pelvic mass, massive ascites and elevated CA-125. A laparoscopic radical surgery was performed, and she was diagnosed with bowel endometriosis. Considering the patient's high recurrence risk indicated by bowel endometriosis, massive ascites, severe adhesions, and dysmenorrhea, six-course gonadotropin-releasing hormone agonists therapy followed by high-dose progestin (two levonorgestrel intrauterine systems and subdermal implants) was administrated postoperatively to improve symptoms and prevent recurrence. No recurrence in bowels was observed by November 2021 (53 months).
Both patient's desire and condition should be considered in the management of symptomatic bowel endometriosis. Optimal surgical removal is of great significance and individualized hormonal therapy may provide an additional component.
子宫内膜异位症是一种困扰约10%育龄期女性的疾病。最严重的子宫内膜异位症形式是深部浸润性子宫内膜异位症(DIE)。肠道是DIE中常见的受累部位。肠道子宫内膜异位症的治疗选择包括手术和药物治疗,这取决于许多因素,如年龄、症状严重程度和妊娠意愿。目前,肠道子宫内膜异位症的个体化综合管理仍在探索中。在此,我们报告一例罕见的肠道子宫内膜异位症病例,该病例通过根治性手术和术后大剂量孕激素治疗,以丰富临床经验。
一名37岁女性因盆腔肿块、大量腹水和CA-125升高,以疑似卵巢恶性肿瘤入院。进行了腹腔镜根治性手术,她被诊断为肠道子宫内膜异位症。考虑到肠道子宫内膜异位症、大量腹水、严重粘连和痛经提示患者复发风险高,术后给予六疗程促性腺激素释放激素激动剂治疗,随后给予大剂量孕激素(两个左炔诺孕酮宫内节育系统和皮下植入剂)以改善症状并预防复发。截至2021年11月(53个月),未观察到肠道复发。
在有症状的肠道子宫内膜异位症管理中,应同时考虑患者的意愿和病情。最佳的手术切除具有重要意义,个体化的激素治疗可能提供额外的治疗手段。